Development of Closed-Loop Insulin Delivery Systems for Type 1 Diabetes Management

This article examines the development and optimization of closed-loop insulin delivery systems, commonly referred to as the "artificial pancreas," for the effective management of Type 1 diabetes mellitus (T1DM). These systems integrate continuous glucose monitoring (CGM), automated insulin pumps, and intelligent control algorithms to maintain blood glucose levels within a safe and optimal range, mimicking the physiological function of a healthy pancreas. Unlike conventional insulin therapy, closed-loop systems respond to real-time glucose fluctuations with minimal human intervention, reducing the risk of hypoglycemia and improving glycemic control. Recent advancements in sensor accuracy, machine learning-based control strategies, and wearable device miniaturization have significantly enhanced the performance and usability of these systems. The article also explores emerging trends such as dual-hormone delivery (insulin and glucagon), interoperability with mobile health platforms, and the role of personalized data analytics in therapy customization. By providing automated, precise, and adaptive glucose regulation, closed-loop insulin delivery systems hold immense potential to improve the quality of life and long-term health outcomes for individuals living with T1DM.